NUV-422

DRUG3 trials

Sponsors

Nuvation Bio Inc.

Conditions

Advanced Breast CancerAdvanced Breast CarcinomaBreast CancerBreast CarcinomaBreast TumorCancer of BreastCancer of ProstateCancer of the Breast

Phase 1

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

TerminatedNCT04541225

Nuvation Bio Inc.Advanced Breast Cancer, Advanced Breast Carcinoma, Breast Cancer +21

Start: 2020-12-08End: 2022-08-31Updated: 2023-07-14

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

WithdrawnNCT05191004

Nuvation Bio Inc.Advanced Breast Cancer, Breast Cancer, Breast Carcinoma +5

Start: 2022-09-30End: 2026-09-30Updated: 2023-07-11

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

WithdrawnNCT05191017

Nuvation Bio Inc.Cancer of Prostate, Cancer of the Prostate, Castrate Resistant Prostate Cancer +5

Start: 2022-09-30End: 2026-07-31Updated: 2022-08-05

Related Papers

Phase 1/2 dose escalation study of NUV-422, a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, in recurrent or refractory (r/r) high-grade gliomas (HGG) and solid tumors.

Journal of Clinical Oncology2022-06-014 citations